ABO and RhD Blood Grouping: Technique, Interpretation and Discrepancy Resolution for NHS Biomedical Scientists

12 min read · Published: 2025-01-08 · Updated: 2026-06-08

ABO grouping is the single most important serological test performed in the transfusion laboratory, because getting it wrong can kill a patient within minutes. For the NHS biomedical scientist (BMS), competent blood grouping is not simply about adding cells to reagents and reading a result; it is about understanding why every check exists, recognising when a reaction does not fit, and never authorising a group you cannot fully explain. This guide covers forward and reverse grouping, RhD typing, column agglutination technology (CAT), interpreting reaction strengths, and the safe, systematic resolution of ABO discrepancies, framed for current 2026 UK practice.

The principle: two halves of one answer

The ABO system is unique in immunohaematology because healthy individuals possess "naturally occurring" antibodies against the A and B antigens they lack. This allows the group to be confirmed twice, from two directions, in a single test:

Forward grouping (cell grouping): the patient's red cells are tested against known reagent anti-A and anti-B antisera (and usually anti-A,B). This detects the antigens on the red cell surface.
Reverse grouping (serum or plasma grouping): the patient's plasma is tested against known reagent A1 and B cells. This detects the antibodies in the plasma.

The two halves must mirror one another. A group O patient has no A or B antigens (negative forward) but has both anti-A and anti-B (positive reverse against both A1 and B cells). The reverse group is therefore a built-in confirmation of the forward group, and the requirement to demonstrate both is central to the British Society for Haematology (BSH) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. The expected pattern is summarised below.

| ABO group | Anti-A (forward) | Anti-B (forward) | A1 cells (reverse) | B cells (reverse) | UK frequency (approx.) | |-----------|:----------------:|:----------------:|:------------------:|:-----------------:|------------------------| | O | Negative | Negative | Positive | Positive | Most common | | A | Positive | Negative | Negative | Positive | Second most common | | B | Negative | Positive | Positive | Negative | Less common | | AB | Positive | Positive | Negative | Negative | Least common |

If the forward and reverse results do not agree with one of these four patterns, an ABO discrepancy exists and the group must not be reported until it is resolved.

RhD typing alongside ABO

After ABO, the RhD antigen is the most clinically significant blood group antigen because of its strong immunogenicity and its central role in haemolytic disease of the fetus and newborn (HDFN). RhD typing is performed by testing the patient's red cells against reagent anti-D.

Key UK practice points for RhD typing:

Two anti-D reagents from different clones are used to type a patient as RhD positive, in line with BSH guidance, to guard against reagent-specific variant reactivity and false results.
The reagents selected for patient testing should not detect the DVI variant. DVI is the partial D type most commonly associated with the production of anti-D, so patients of this type are best managed as RhD negative to avoid alloimmunisation. (Donor testing uses the opposite approach, deliberately detecting weak and partial D so that any D-bearing unit is labelled positive.)
A reaction that is clearly weaker than expected, or discrepant between the two reagents, raises the possibility of a weak D or partial D phenotype. Such samples are referred for further investigation; pending resolution the patient is treated as RhD negative and given RhD-negative components and, where relevant, anti-D immunoglobulin prophylaxis.
RHD genotyping, available through NHS Blood and Transplant (NHSBT) Red Cell Immunohaematology (RCI) reference laboratories, is increasingly used to resolve serological weak D phenotypes and to inform safe transfusion and prophylaxis decisions.

Always interpret a "negative" RhD result with care: a genuine RhD-negative typing in a patient still requires the correct negative and positive controls to have behaved correctly before it can be trusted.

Column agglutination technology (CAT)

Most UK transfusion laboratories perform routine grouping using column agglutination technology, also called gel or glass-bead microcolumn technology, on automated analysers. Microtubes (cards or cassettes) contain a matrix of gel or beads suspended in buffer, with reagent incorporated into the column or added at the top.

How CAT separates positive from negative:

1. Red cells and reagent (or plasma) are dispensed into the reaction chamber above the column and incubated as required. 2. The card is centrifuged. Agglutinated cells are trapped by the matrix according to clump size; unagglutinated cells pass freely through to the bottom. 3. The position of the cells gives the result and a graded strength.

Reading the column:

Strong positive (4+): a solid band of cells held at the very top of the column.
Weaker positives (3+, 2+, 1+): agglutinates distributed progressively further down the gel.
Negative: a clean, compact pellet of cells at the bottom, with no cells trapped in the matrix.
Mixed-field: a population of cells at the top and a separate pellet at the bottom, indicating two red cell populations (for example, recent transfusion of group-different cells, a transplant, or a true subgroup).

CAT offers a stable, photographable end point that supports automation, audit trails and standardised interpretation, which is why the BSH guidelines and the JPAC Guidelines for the Blood Transfusion Services in the United Kingdom (the Red Book) state that fully automated ABO and D grouping should be used wherever possible to minimise interpretation and transcription errors. Conventional tube technique remains a valuable manual backup and is sometimes more sensitive for certain weak antigen–antibody reactions, so a competent BMS should understand both.

Reading and grading reactions

Confident, reproducible reading is a craft. Whether on an analyser or by manual tube, grade every reaction and record it; do not simply call "positive" or "negative".

4+: one solid agglutinate, clear supernatant (or a solid band at the top of the gel).
3+: several large agglutinates.
2+: medium agglutinates, turbid background.
1+ / weak (w+): small agglutinates against a sea of free cells; the commonest grade to be missed or over-called.
Negative: smooth cell suspension or a clean pellet, no agglutination.
Mixed-field: two populations, always investigate and explain.

Be alert to artefacts that mimic or mask true reactions: rouleaux (cells stacked like coins, often from raised plasma proteins) can suggest false agglutination in reverse grouping; cold agglutinins can cause unexpected reactions at room temperature; and fibrin or sample quality issues can trap cells misleadingly. Saline replacement, washing and pre-warming are standard techniques to distinguish these from genuine agglutination.

Resolving ABO discrepancies safely

An ABO discrepancy is any failure of the forward and reverse groups to match a recognised pattern. The golden rule is absolute: never issue ABO-incompatible blood, and never authorise a group you cannot explain. When a discrepancy is flagged, do not edit the result to force agreement.

A structured approach:

1. Stop and check the obvious. Confirm sample identity and integrity, correct reagents and cells, no clerical or analyser error, and that the result is genuinely repeatable. A surprising number of "discrepancies" are clerical or technical. 2. Recheck against history. Compare with any previous group on the laboratory information management system (LIMS). A new group that differs from a reliable historical group is a major red flag for wrong blood in tube (WBIT) and demands a fresh sample. 3. Categorise the discrepancy. Decide whether the problem lies in the forward group (extra or missing antigen reaction), the reverse group (extra or missing antibody reaction), or both. 4. Consider the common causes (see table below) and select targeted investigations. 5. Provide urgent cover safely. If red cells are needed before resolution, issue group O red cells (RhD negative unless the patient's D status is reliably known), and group-compatible plasma/platelets, while investigation continues. 6. Refer when needed. Send unresolved or complex cases to the NHSBT RCI reference laboratory rather than guessing.

| Discrepancy type | Common causes | First-line investigation | |------------------|---------------|--------------------------| | Missing/weak reverse antibody | Neonates and infants; elderly/immunosuppressed; hypogammaglobulinaemia; recent stem cell transplant | Extend incubation, test at lower temperature, use larger plasma volume; review clinical history | | Extra reverse reactions | Cold autoantibodies; rouleaux; alloantibodies (e.g. anti-A1 in A2 subgroups); passive ABO antibodies | Pre-warm, saline replacement, antibody screen/ID, test against A1 and A2 cells | | Weak/missing forward antigen | ABO subgroups (A2, A3, Ax, etc.); leukaemia/disease-related antigen depression; recent transfusion | Repeat with anti-A,B, extended technique; review history; consider molecular grouping | | Extra forward reactions | Recent transfusion (mixed-field); acquired B phenomenon; autoagglutination; reagent contamination | Examine for mixed-field, DAT, wash cells, review history | | Whole-pattern mismatch | WBIT, transcription error, transplant | New sample, repeat from scratch, confirm identity |

Document every step. Under ISO 15189:2022, the international standard to which UK transfusion laboratories are accredited by the United Kingdom Accreditation Service (UKAS), the rationale for accepting a final group must be traceable.

Controls, governance and the wider safety system

Blood grouping does not stand alone; it sits inside a regulated quality system designed to prevent the catastrophic outcome of an ABO-incompatible transfusion.

Controls: internal quality control (IQC) is run with known group cells, and the analyser's internal controls (and a negative reagent/auto control where appropriate) must pass before results are accepted. Participation in external quality assessment (EQA) through UK NEQAS for Blood Transfusion Laboratory Practice (BTLP) is an essential, ongoing check on grouping and interpretation performance.
Group-check / second sample: to defend against WBIT, BSH guidance recommends that, unless a secure electronic patient identification system is in place, a second independent sample is obtained to confirm the ABO group of a first-time patient before transfusion of non-urgent red cells. This must never delay genuinely urgent transfusion.
Electronic issue (electronic crossmatch): patients with a confirmed, valid ABO/D group and a negative antibody screen, who meet defined criteria, may have blood issued electronically by the LIMS without a serological crossmatch. The integrity of the underlying group is the foundation of this process.
Sample retention: the pre-transfusion sample is retained for at least several days post-transfusion so the group can be repeated if a reaction occurs.
Regulation and haemovigilance: the Blood Safety and Quality Regulations 2005 (BSQR), overseen by the Medicines and Healthcare products Regulatory Agency (MHRA), require full traceability of components, with records kept for not less than 30 years. The Serious Hazards of Transfusion (SHOT) scheme analyses errors nationally. SHOT data continue to show that WBIT and identification failures, not laboratory technique alone, are leading causes of ABO incompatibility, and that laboratory checks detect the majority of WBIT errors before harm occurs, underlining the BMS's role as a critical safety barrier.

Frequently Asked Questions

Why do we perform both forward and reverse ABO grouping?

The two tests check the same answer from opposite directions: forward grouping detects A and B antigens on the red cells, while reverse grouping detects the corresponding anti-A and anti-B antibodies in the plasma. Because they must agree, the reverse group is a powerful internal cross-check that catches sampling errors, technical faults and unexpected biology. UK practice requires both to be demonstrated before an ABO group can be reported.

What is an ABO discrepancy and what should I do first?

An ABO discrepancy is any result where the forward and reverse groups do not match one of the four recognised patterns. The first step is always to stop, confirm the sample identity and integrity, check the reagents and analyser, and repeat the test, because many discrepancies are clerical or technical rather than biological. Never force the result to agree, and if red cells are needed urgently before resolution, issue group O.

Why are two different anti-D reagents used for RhD typing?

Using two anti-D reagents from different clones protects against reagent-specific variation, where a single clone might react abnormally with a D variant and give a false positive or negative. For patient typing, the reagents are chosen so they do not detect the DVI partial D variant, because DVI individuals can make anti-D and are safest managed as RhD negative. This two-reagent approach is standard UK practice under BSH guidance.

How do I read a column agglutination (gel) card?

Cells held at the top of the column indicate a strong positive, agglutinates trapped progressively lower indicate weaker positives, and a clean pellet at the bottom is a negative result. A separate population at the top and a pellet at the bottom is a mixed-field reaction, which always needs explanation, for example recent transfusion or a transplant. Always grade and record the reaction strength rather than calling a bare positive or negative.

What is "wrong blood in tube" and why does it matter so much?

Wrong blood in tube (WBIT) means the blood in the sample tube is not from the patient named on the label, almost always due to a patient identification failure at the point of sampling. It is dangerous because a perfectly performed group on the wrong sample can lead directly to an ABO-incompatible transfusion. SHOT haemovigilance data show WBIT is a leading cause of ABO incompatibility, which is why group-check second samples and rigorous identity checks are so heavily emphasised.

Can a patient ever be safely transfused before an ABO discrepancy is resolved?

Yes, if clinically urgent. Group O red cells (RhD negative unless the patient's D status is reliably known) and ABO-compatible plasma and platelets can be issued while the investigation continues, because group O red cells carry neither A nor B antigen. The discrepancy must still be fully investigated and resolved, with referral to the NHSBT Red Cell Immunohaematology laboratory where needed, and every decision documented.

Further training

This article is part of the NHS Laboratory Training cluster. To build a complete picture of safe transfusion and immunohaematology practice, continue with these related guides: